In Vivo Hematopoietic Stem Cell Gene Therapy of Beta-Thalassemia

β-地中海贫血的体内造血干细胞基因治疗

基本信息

批准号：
9000884
负责人：
ANDRE Michael LIEBER
金额：
$ 38.63万
依托单位：
UNIVERSITY OF WASHINGTON
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-06-01 至 2020-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9000884
关键词：
AMD3100 Adenovirus Vector Adult Back Bone Marrow Bone Marrow Purging CD34 gene CD46 Antigen CSF3 gene Cells Collection Communicable Diseases DNA DNA cassette Erythroid Erythroid Cells Erythropoiesis Gene Delivery Gene Targeting Gene Transduction Agent Gene Transfer Genes Genetic Genomic Segment Globin Goals Hematopoietic Stem Cell Mobilization Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Hemoglobin Hemolytic Anemia Hereditary Disease Home environment Human In Vitro Injection of therapeutic agent Lentivirus Vector Malignant Neoplasms Mediating Modeling Morbidity - disease rate Mus Mutation Patients Production Proteins Proto-Oncogenes Risk Safety Side Site Sleeping Beauty Stream System Systems Integration Testing Thalassemia Therapeutic Time Transfusion Transgenes Transgenic Mice Transgenic Model Transplantation Transposase Ursidae Family base beta Thalassemia cellular transduction cost epigenetic regulation gene therapy genome editing genotoxicity gutless adenoviral vector homologous recombination in vivo intravenous injection mouse model peripheral blood public health relevance receptor retransplantation transcription activator-like effector nucleases transgene expression vector

项目摘要

DESCRIPTION (provided by applicant) Hematopoietic stem cells (HSCs) are an important target for the gene therapy of infectious diseases, genetic disorders, and cancer. In vivo genome editing of HSCs has major advantages over currently used approaches that involve the collection of HSCs from patients, their in vitro culture/transduction, and retransplantation into myelo-conditioned patients. We have developed a new in vivo approach for HSC transduction, which is based on the GCSF/AMD3100-mediated mobilization of HSCs from the bone marrow into the peripheral blood stream and the intravenous injection of an HSC-targeting, helper-dependent adenovirus vector (HD-Ad5/35). The central goal of this proposal is to increase the percentage of stably in vivo HD-Ad5/35 - transduced HSCs while avoiding potential genotoxicity. We plan to achieve this through i) optimization of HSC mobilization and in vivo HSC transduction, ii) optimization of transgene integration through stimulation of homologous recombination, and iii) incorporation into HD- Ad5/35 vectors of systems that allow for the in vivo selection or expansion of stably transduced cells. Based on these studies, we will generate and test HD-Ad5/35 vectors for in vivo gene therapy of b-thalassemia.

描述（由申请人提供）造血干细胞 (HSC) 是传染病、遗传性疾病和癌症基因治疗的重要靶点，与目前使用的从患者体内收集 HSC 并进行体外培养的方法相比，HSC 的体内基因组编辑具有重大优势。我们开发了一种新的体内 HSC 转导方法，该方法基于 GCSF/AMD3100 介导的 HSC 从骨骼中的动员。该提案的中心目标是增加体内稳定的 HD-Ad5/35 的百分比。我们计划通过 i) 优化 HSC 动员和体内 HSC 转导，ii) 通过刺激同源重组优化转基因整合来实现这一目标。 iii) 纳入HD-Ad5/35载体系统，允许体内选择或扩增稳定转导的细胞。基于这些研究，我们将生成并测试用于b的体内基因治疗的HD-Ad5/35载体。 -地中海贫血。